简体中文

AC-6-核多点型

同义词 无 None
描述
大小不一的粗斑点弥散分布于核质内；核仁通常无染色。分裂期细胞（中期、后期、末期）的染色质团无染色，但其周围胞质可见染色。
Variable sized coarse speckles dispersed throughout the nucleoplasm. The nucleoli are typically not stained. The chromatin mass of mitotic cells (metaphase, anaphase, and telophase) is, in contrast to the cytoplasm surrounding the chromatin mass, not stained.
抗原相关性 Sp100, Sp140, NXP-2 Sp100, Sp140, NXP-2

  • 临床相关性

    一级信息

    关于临床相关性和缩写列表

    Clinical Relevance

    First level information

    About Clinical Relevance & List of Abbreviations


  • ►广泛见于多种自身免疫性疾病，包括原发性胆汁性胆管炎（PBC）、特发性炎性肌病（IIM）、皮肌炎（DM）及其他炎症性疾病 [1]
    ►临床疑似原发性胆汁性胆管炎时，建议加做抗‑Sp100 及抗‑Sp140 抗体检测；优先推荐检测抗‑Sp100 抗体，该抗体通常与 PBC 相关，且具备预后价值；Sp100（以及 Sp140）抗原可包含于疾病特异性免疫检测组合（即肝病谱）[2‑4]
    ►临床疑似皮肌炎时，建议加做抗‑NXP‑2 抗体检测；抗‑NXP‑2 抗体对特发性炎性肌病具有高度特异性，约见于 1/3 青少年皮肌炎患者；据文献报道，成人特发性炎性肌病患者该抗体阳性与恶性肿瘤相关 [5‑7]


    ▶Found in a broad spectrum of autoimmune diseases, including primary biliary cholangitis (PBC), idiopathic inflammatory myopathies (IIM), dermatomyositis (DM), as well as other inflammatory conditions [1]
    ▶If PBC is clinically suspected, follow-up tests for antibodies to Sp100 and Sp140 are recommended; in particular Sp100 antibodies are recommended as they are typically associated with PBC and have prognostic value; the Sp100 (and Sp140) antigen may be included in disease specific immunoassays (i.e., liver profile) [2-4]
    ▶If DM is clinically suspected, it is recommended to perform a follow-up test for NXP-2 antibodies; these NXP-2 antibodies are highly specific for IIM, are found in up to one third of patients with juvenile DM, and have been reported to be associated with malignancies in adult IIM patients [5-7]


  • 二级信息
    Second level information
  • 无
    None
  • 参考文献
  • 1.Cozzani E, Drosera M, Riva S, Parodi A. Analysis of a multiple nuclear dots pattern in a large cohort of dermatological patients. Clin Lab. 2012;58:329-32
    2.Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:125-31
    3.Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One. 2014;9:e101916
    4.Rigopoulou EI, Bogdanos DP. Role of autoantibodies in the clinical management of primary biliary cholangitis. World J Gastroenterol. 2023;29:1795-810
    5.Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, Tincani A, Ross SJ, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14:R97
    6.Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29:662-73
    7.Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710-3

FAQ